A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

AIMS: To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus. METHODS AND RESULTS: Miner Alocorticoid Receptor antagonist...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Heart J
Hlavní autoři: Filippatos, Gerasimos, Anker, Stefan D., Böhm, Michael, Gheorghiade, Mihai, Køber, Lars, Krum, Henry, Maggioni, Aldo P., Ponikowski, Piotr, Voors, Adriaan A., Zannad, Faiez, Kim, So-Young, Nowack, Christina, Palombo, Giovanni, Kolkhof, Peter, Kimmeskamp-Kirschbaum, Nina, Pieper, Alexander, Pitt, Bertram
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Fasttrack Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946749/
https://ncbi.nlm.nih.gov/pubmed/27130705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehw132
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky